Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Robb

Showing results (571-580 of 731) with videos related to

Pageof 74
Sort By:
Plos One|May 19, 2016
Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I TrialAgricola Joachim, Asli Bauer, Sarah Joseph, et al.
Plos Pathogens|August 4, 2016
Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV InfectionKorey R Demers, George Makedonas, Marcus Buggert, et al.
The Journal of Infectious Diseases|October 29, 2002
Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cellsMary A Marovich, John R Mascola, Michael A Eller, et al.
AIDS Research and Human Retroviruses|August 12, 2003
A new circulating recombinant form, CRF15_01B, reinforces the linkage between IDU and heterosexual epidemics in ThailandSodsai Tovanabutra, Veerachai Watanaveeradej, Kwanjai Viputtikul, et al.
The Journal of Infectious Diseases|February 25, 2016
Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or PolyphosphazeneRobert J O'Connell, Jean-Louis Excler, Victoria R Polonis, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|April 8, 2022
HIV pre-exposure prophylaxis was associated with no impact on sexually transmitted infection prevalence in a high-prevalence population of predominantly men who have sex with men, Germany, 2018 to 2019Hendrik Streeck, Klaus Jansen, Trevor A Crowell, et al.
Plos One|May 22, 2026
HIV incidence among sexually active young males and females in Kisumu County, Western KenyaJohn Owuoth, Chiaka Nwoga, Valentine Sing'oei, et al.
Ebiomedicine|January 20, 2015
Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting VirusesSusan Zolla-Pazner, Paul T Edlefsen, Morgane Rolland, et al.
Plos One|December 30, 2011
Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in ThailandPunnee Pitisuttithum, Supachai Rerks-Ngarm, Valai Bussaratid, et al.
AIDS (London, England)|February 1, 2023
Brain volumetrics differ by Fiebig stage in acute HIV infectionJacob Bolzenius, Carlo Sacdalan, Lishomwa C Ndhlovu, et al.
Pageof 74

Showing results (571-580 of 731) with videos related to

Sort By:
Pageof 74
Plos One|May 19, 2016
Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I TrialAgricola Joachim, Asli Bauer, Sarah Joseph, et al.
Plos Pathogens|August 4, 2016
Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV InfectionKorey R Demers, George Makedonas, Marcus Buggert, et al.
The Journal of Infectious Diseases|October 29, 2002
Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cellsMary A Marovich, John R Mascola, Michael A Eller, et al.
AIDS Research and Human Retroviruses|August 12, 2003
A new circulating recombinant form, CRF15_01B, reinforces the linkage between IDU and heterosexual epidemics in ThailandSodsai Tovanabutra, Veerachai Watanaveeradej, Kwanjai Viputtikul, et al.
The Journal of Infectious Diseases|February 25, 2016
Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or PolyphosphazeneRobert J O'Connell, Jean-Louis Excler, Victoria R Polonis, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|April 8, 2022
HIV pre-exposure prophylaxis was associated with no impact on sexually transmitted infection prevalence in a high-prevalence population of predominantly men who have sex with men, Germany, 2018 to 2019Hendrik Streeck, Klaus Jansen, Trevor A Crowell, et al.
Plos One|May 22, 2026
HIV incidence among sexually active young males and females in Kisumu County, Western KenyaJohn Owuoth, Chiaka Nwoga, Valentine Sing'oei, et al.
Ebiomedicine|January 20, 2015
Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting VirusesSusan Zolla-Pazner, Paul T Edlefsen, Morgane Rolland, et al.
Plos One|December 30, 2011
Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in ThailandPunnee Pitisuttithum, Supachai Rerks-Ngarm, Valai Bussaratid, et al.
AIDS (London, England)|February 1, 2023
Brain volumetrics differ by Fiebig stage in acute HIV infectionJacob Bolzenius, Carlo Sacdalan, Lishomwa C Ndhlovu, et al.
Pageof 74